Arrowhead Pharmaceuticals (ARWR) Other financing activities (2010 - 2026)

Arrowhead Pharmaceuticals' Other financing activities history runs 10 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• Quarterly Other financing activities rose 146.65% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.9 million (up 880.42% YoY) and the FY2025 annual result came in at $25.0 million, changed N/A from the prior year.
• Other financing activities was $10.1 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $21.7 million in the prior quarter.
• Across five years, Other financing activities topped out at $249.4 million in Q1 2023 and bottomed at -$247.8 million in Q2 2023.
• A 5-year average of $3.5 million and a median of $2.2 million in 2022 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 6585.18% in 2023, while the deepest fall reached 6540.79% in 2023.
• Arrowhead Pharmaceuticals' Other financing activities stood at $576000.0 in 2022, then plunged by 487.5% to -$2.2 million in 2023, then surged by 1220.07% to $25.0 million in 2024, then declined by 13.01% to $21.7 million in 2025, then sank by 53.35% to $10.1 million in 2026.
• Business Quant data shows ARWR's Other financing activities at $10.1 million in Q1 2026, $21.7 million in Q2 2025, and -$21.7 million in Q1 2025.